Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Brent Oil Fund LP (BNO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

United States Brent Oil Fund LPTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

United States Brent Oil Fund LP vs Inovio Pharmaceuticals Inc — how do they compare? United States Brent Oil Fund LP trades at $50.74, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

BNOINO
Sector
Commodities - EnergyHealth
52-Week High
$60.13$2.87
52-Week Low
$27.20$0.66
Market Cap
$78.55M
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Brent Oil Fund LP

BNO, tracking Brent crude oil futures, trades at $50.73, up 1.24% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights supply disruptions from the Strait of Hormuz standoff and OPEC's lowered demand forecasts, creating volatility. The stock lacks traditional financial ratios as it is an ETF, with performance tied directly to oil price movements and geopolitical developments.

Outlook hinges on oil market dynamics, with upside from sustained supply risks but downside from demand weakness. Risks include Middle East tensions and inventory builds. Analysts monitor EIA data and OPEC actions for direction, with current sentiment mixed amid headline-driven price swings.

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Returns comparison

Trailing returns across standard periods

About United States Brent Oil Fund LP

BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.

Read more on BNO

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO